---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-238295"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2023-09-20T23:59:59+00:00"
generated_at: "2026-06-10T12:13:30.869632+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibikase provides pipeline updates after sharp stock decline; 201 Trial enrollment at 28 patients

## Summary
- Stock dropped dramatically over last 8 trading sessions; no identifiable cause for volatility.
- Risvodetinib 201 Trial: 28 of 120 patients enrolled/screening; one completed 12-week dosing; portal added 50 potential participants in Sept.
- Safety data for risvodetinib presented on 119 people at MDS Congress; no side effects of clinical significance.
- IkT-001Pro: FDA meeting request steps completed; bioequivalence study to 600 mg imatinib mesylate due early Q4 2023.
- Cash position sufficient to fund operations into Q4 2024.

## SEC filing metadata
- accession: 0001193125-23-238295
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2023-09-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312523238295/0001193125-23-238295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312523238295/d509876d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-238295
- JSON: https://secwatch.observer/filing/0001193125-23-238295.json
- Plain text: https://secwatch.observer/filing/0001193125-23-238295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.